leading tirzepatide law firm Lilly's Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP FDA Crackdown Puts Pressure on

Larsen said the company sees a "low single-digit" impact from generics and described its savings card as the "leading tactic" in Canada, with "very good uptake" reported for both Ozempic and Wegovy [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]

Sandborn WJ, Ghosh S, Panes J, Schreiber S, DHaens G, Tanida S, et al

Early synthetic GLP-1 receptor agonists demonstrated promise in extending receptor activation, but limited half-life restricted their utility

17,21 Significant reductions in BP as a consequence of weight loss also allow health care providers to manage hypertension more effectively, potentially decreasing the need for multiple antihypertensive medications